RESUMO

In triple-negative breast cancer (TNBC), only 30% of patients treated with neoadjuvant chemotherapy achieve a pathological complete response after treatment and more than 90% die due to metastasis formation. The diverse clinical responses and metastatic developments are attributed to extensive intrapatient genetic heterogeneity and tumor evolution acting on this neoplasm. In this work, we aimed to evaluate genomic alterations and tumor evolution in TNBC patients with aggressive disease. We sequenced the whole exome of 16 lesions from four patients who did not respond to therapy, and took several follow-up samples, including samples from tumors before and after treatment, as well as from the lymph nodes and skin metastases. We found substantial intrapatient genetic heterogeneity, with a variable tumor mutational composition. Early truncal events were MCL1 amplifications. Metastatic lesions had deletions in RB1 and PTEN, along with TERT, AKT2, and CCNE1 amplifications. Mutational signatures 06 and 12 were mainly detected in skin metastases and lymph nodes. According to phylogenetic analysis, the lymph node metastases occurred at an early stage of TNBC development. Finally, each patient had three to eight candidate driving mutations for targeted treatments. This study delves into the genomic complexity and the phylogenetic and evolutionary development of aggressive TNBC, supporting early metastatic development, and identifies specific genetic alterations associated with a response to targeted therapies.

RESUMO

Resumen En los últimos años el estudio de los ácidos nucleicos circulantes ha tenido grandes avances en el campo de la oncología, lo que ha permitido avanzar de forma importante en las aplicaciones clínicas de la biopsia líquida en diferentes áreas como el pronóstico, la estadificación, la predicción de recurrencia, la selección y monitorización de tratamientos, entre otros. Lo anterior se debe en gran parte al desarrollo de nuevas y mejores tecnologías, algunas de las cuales incluso han sido autorizadas para el diagnóstico y seguimiento clínico de ciertos tipos de cáncer. No obstante, la utilización de la biopsia líquida como herramienta de apoyo clínico sigue siendo objeto de estudio. Debido a la importancia que ha cobrado este avance tecnológico a nivel mundial, se realizó una revisión de literatura con el fin de establecer el estado actual del uso de biopsia líquida en oncología, así como sus aplicaciones clínicas actuales, con un énfasis en Latinoamérica.

Abstract In recent years, the study of circulating nucleic acids has made great progress in the field of oncology, allowing for significant advances in clinical applications of liquid biopsy in diverse areas such as prognosis, staging, recurrence prediction, selection and monitoring of treatments, among others. This advance is largely due to the development of new and better technologies, some of which have even been validated for the diagnosis and clinical follow-up of certain types of cancer. However, the use of liquid biopsy as an additional tool in clinical oncology remains under study. Given the worldwide importance of this technological advance, a literature review was conducted to establish the current status of the use of liquid biopsy in oncology, as well as its current clinical applications, with a particular focus on Latin America.

Assuntos

RESUMO

Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promotes a clinical heterogeneity that further complicates treatment. We performed a detailed whole exome sequencing profile of 29 Mexican patients with long follow-up TNBC to identify genomic alterations associated with overall survival (OS), disease-free survival (DFS), and pathologic complete response (PCR), with the aim to define their role as molecular predictive factors of treatment response and prognosis. We detected 31 driver genes with pathogenic mutations in TP53 (53%), BRCA1/2 (27%), CDKN1B (9%), PIK3CA (9%), and PTEN (9%), and 16 operative mutational signatures. Moreover, tumors with mutations in BRCA1/2 showed a trend of sensitivity to platinum salts. We found an association between deficiency in DNA repair and surveillance genes and DFS. Across all analyzed tumors we consistently found a heterogeneous molecular complexity in terms of allelic composition and operative mutational processes, which hampered the definition of molecular traits with clinical utility. This work contributes to the elucidation of the global molecular alterations of TNBC by providing accurate genomic data that may help forthcoming studies to improve treatment and survival. This is the first study that integrates genomic alterations with a long follow-up of clinical variables in a Latin American population that is an underrepresented ethnicity in most of the genomic studies.

Assuntos

RESUMO

BACKGROUND: Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors such as abiraterone and enzalutamide, for which androgen receptor splice variant 7 (AR-V7) has emerged as a biomarker for primary resistance. Our study sought to analyze the potential economic impact of the use of AR-V7 detection as a treatment indicator in patients with mCRPC in three Latin American countries. MATERIALS AND METHODS: A hypothetical cost prediction model for the use of noninvasive circulating tumor cell-based AR-V7 testing as a treatment indicator for patients eligible for treatment with abiraterone/enzalutamide was conducted using available information on treatment and testing costs from Mexico, Argentina, and Colombia. RESULTS: At an estimated prevalence of AR-V7 positivity of 20%, the use of upfront AR-V7 genetic testing resulted in annual net savings of $9,801,669.97, $6,390,055.75, and $3,096,780.91 in Mexico, Argentina, and Colombia, respectively. A direct relationship between AR-V7 positivity prevalence and net savings was found. CONCLUSION: The use of a noninvasive AR-V7 detection assay as a treatment indicator tool in patients eligible for treatment with abiraterone or enzalutamide in Latin America could be a cost-effective approach for the management of these patients. Additional efforts are needed to accurately determine the incidence of castration-resistant prostate cancer cases and the prevalence of AR-V7 positivity in Latin America in order to predict the potential economic benefit of its clinical use. IMPLICATIONS FOR PRACTICE: In Latin America, prostate cancer is the most frequently diagnosed cancer in men, and the burden of this disease is expected to double in this region by 2030. Noninvasive detection of androgen receptor splice variant 7 (AR-V7) is being currently validated as a predictive biomarker for benefit with androgen receptor signaling inhibitor therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). This hypothetical cost-saving analysis shows that AR-V7 testing in peripheral blood of patients with CRPC eligible for treatment with abiraterone or enzalutamide might represent a cost-effective strategy to select patients who will benefit from AR-axis-directed treatment in three Latin American countries.

Assuntos

RESUMO

Hereditary breast and ovarian cancer syndrome (HBOC) represents 5⁻10% of all patients with breast cancer and is associated with high-risk pathogenic alleles in BRCA1/2 genes, but only for 25% of cases. We aimed to find new pathogenic alleles in a panel of 143 cancer-predisposing genes in 300 Mexican cancer patients with suspicion of HBOC and 27 high-risk patients with a severe family history of cancer, using massive parallel sequencing. We found pathogenic variants in 23 genes, including BRCA1/2. In the group of cancer patients 15% (46/300) had a pathogenic variant; 11% (33/300) harbored variants with unknown clinical significance (VUS) and 74% (221/300) were negative. The high-risk group had 22% (6/27) of patients with pathogenic variants, 4% (1/27) had VUS and 74% (20/27) were negative. The most recurrent mutations were the Mexican founder deletion of exons 9-12 and the variant p.G228fs in BRCA1, each found in 5 of 17 patients with alterations in this gene. Rare VUS with potential impact at the protein level were found in 21 genes. Our results show for the first time in the Mexican population a higher contribution of pathogenic alleles in other susceptibility cancer genes (54%) than in BRCA1/2 (46%), highlighting the high locus heterogeneity of HBOC and the necessity of expanding genetic tests for this disease to include broader gene panels.

RESUMO

La reacción en cadena de la polimerasa (PCR) es la técnica más importante en Biología Molecular. Su principal deficiencia es la susceptibilidad a la contaminación de la muestra, ya sea con productos de amplificación generados en reacciones previas o con material genético proveniente de otras muestras. Se entiende por contaminación a la presencia indeseada de moléculas de ADN o ARN, que pueden actuar como templados en reacciones de amplificación. El objetivo del trabajo fue demostrar la importancia de la implementación de un control de contaminación ambiental periódico monitoreando la integridad del circuito de PCR. Para ello, se hisoparon puntos correspondientes a diferentes áreas de trabajo y se investigó la presencia de amplicones mediante PCR Real Time en Lighcycler 2.0, Roche® y Ampliprep Cobas s201, Roche®. En puntos críticos del circuito (flujo laminar o la cabina de seguridad del área de pre-PCR) no se detectaron amplicones, aunque sí se hallaron en las mesadas y heladeras. En el resto del circuito, la distribución de los amplicones fue variable. De esta forma se demuestra la importancia de la realización de un control de contaminación ambiental periódico en laboratorios que realizan la técnica de PCR, pudiendo detectar contaminación de forma precoz y tomar acciones correctivas a tiempo.

Polymerase chain reaction (PCR) is the most important technique in Molecular Biology. Its main deficiency is susceptibility to contamination of the sample, either with amplification products generated in previous reactions or with genetic material from other samples. Contamination is understood as the undesired presence of DNA or RNA molecules, which may act as annealing in amplification reactions. The objective of this work is to demonstrate the importance of implementing a periodic environmental pollution control by monitoring the integrity of the PCR. To do this, different areas of work were swabbed and the presence of amplicons were investigated by Real Time PCR in Lighcycler 2.0, Roche® and Ampliprep Cobas s201, Roche®. At critical points in the circuit (laminar flow or pre-PCR area booth) no amplicons were detected, although they were found in countertops and refrigerators. In the rest of the circuit, the distribution of the amplicons was variable. Thus, the importance of conducting a periodic environmental contamination control in laboratories that perform the PCR technique is demonstrated, enabling early detection contamination and corrective actions being taken on time.

A reação em cadeia da polimerase (PCR) é a técnica mais importante em Biologia Molecular. Sua principal deficiência é a suscetibilidade à contaminação da amostra, seja com produtos de amplificação gerados em reações prévias ou com material genético em reações prévias ou com material genético proveniente de outras amostras. Entende-se por contaminação a presença não desejada de moléculas de DNA ou ARN, que podem agir como temperados em reações de amplificação. O objetivo do trabalho foi demonstrar a importância da implementação de um controle de contaminação ambiental periódico monitorando a integridade do circuito de PCR. Para isso, se fez esfregaço de pontos correspondentes a diferentes áreas de trabalho e foi investigada a presença de amplicons mediante PCR Real Time em Lighcycler 2.0, Roche® e Ampliprep Cobas s201, Roche®. Em pontos críticos do circuito (fluxo laminar ou a cabine de segurança da área de pré-PCR), não foram detectados amplicons, apesar de serem encontrados nas bancadas e refrigeradores. No resto do circuito, a distribuição dos amplicons foi variável. Assim mostra a importância da realização de um controle de contaminação ambiental periódico em laboratórios que realizam a técnica de PCR, podendo detectar a contaminação de forma precoce e tomar ações corretivas a tempo.

Assuntos

RESUMO

In Latin America (LA), cancer is the second leading cause of death, and little is known about the capacities and needs for the development of research in the field of cancer genomics. In order to evaluate the current capacity for and development of cancer genomics in LA, we collected the available information on genomics, including the number of next-generation sequencing (NGS) platforms, the number of cancer research institutions and research groups, publications in the last 10 years, educational programs, and related national cancer control policies. Currently, there are 221 NGS platforms and 118 research groups in LA developing cancer genomics projects. A total of 272 articles in the field of cancer genetics/genomics were published by authors affiliated to Latin American institutions. Educational programs in genomics are scarce, almost exclusive of graduate programs, and only few are concerning cancer. Only 14 countries have national cancer control plans, but all of them consider secondary prevention strategies for early diagnosis, opportune treatment, and decreasing mortality, where genomic analyses could be implemented. Despite recent advances in introducing knowledge about cancer genomics and its application to LA, the region lacks development of integrated genomic research projects, improved use of NGS platforms, implementation of associated educational programs, and health policies that could have an impact on cancer care.

Assuntos

RESUMO

Several different cytokines trigger the development of determined cell subsets in BALT of growing Wistar rats. Early appearance (4 days post partum) of gammadeltaT cells in BALT has been shown, as well as its role in up-regulating TNF-alpha production. In the present report, we studied in the BALT: (1) the profile of the cytokines, TNF-alpha, INF-alpha and IL-10 and (2) in TCR gammadelta+ cells, the existence of a colocalization with TNF-alpha as well as with INF-gamma. All the cytokines studied were observed at an early stage of BALT development by immunohistochemistry and in bronchoalveolar cells (BAL cells) by flow cytometry and western blot. (1) The principal cytokine found at 4 days of age in BALT cells was TNF-alpha that increases along BALT development. The same behavior was found for cells containing IL-10 and INF-gamma. (2) TCR gammadelta+ cells colocalize mainly with TNF-alpha as it has been shown by immunohistochemistry in BALT and by flow cytometry when we studied BAL. The early appearance of TNF-alpha concomitant with TCR gammadelta+ cell suggests an important role for this cytokine along BALT development. Moreover, mutual regulation between them exists taking part in the immune surveillance and repair of damaged epithelia.

Assuntos